Released May 8, 2025, after the close
10-Q filed May 8, 2025, 38 days after period end · 0001628280-25-023927
Q1 2025 · 10-Q
Revenue$41.46M$41.46M −7.6% vs Q1 2024−27.9% vs Q4 2024
Net Income-$11.40M-$11.40M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.09-$0.09 N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit$20,157,000−12.4%
Operating Income-$14,975,000N/M
Operating Cash Flow-$125,000N/M
Free Cash Flowderived-$974,000N/M
Margins · derived
Gross margin48.6%−2.7 pt vs Q1 2024
Operating margin-36.1%−12.2 pt vs Q1 2024
Net margin-27.5%−13.8 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $41.46M | $44.86M | $37.09M | $35.06M |
| Net Income | -$11.40M | -$6.17M | -$6.81M | -$2.16M |
| EPS Diluted | -$0.09 | -$0.05 | -$0.05 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR